billHR1922Event Thursday, March 6, 2025Analyzed

Ensuring Access to Essential Drugs Act

Neutral

Summary

HR1922 is an early-stage bill referred to committee with no market impact. It would exempt certain orally administered brand-name drugs from Medicare Part D rebate obligations, but no hearings, votes, or further action have occurred since introduction on 2025-03-06.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR1922 is in the earliest legislative stage with no momentum.
  • 2.The exemption applies only to a narrow subset of drugs with a specific CMS reclassification — no affected drugs or companies are identifiable from the bill text.
  • 3.No immediate market impact; the bill is purely procedural at this point.

Market Implications

No market implications at this stage. The bill does not name any companies, authorize spending, or create a clear revenue mechanism for any publicly traded entity. Retail investors should not adjust positions based on this bill alone.

Full Analysis

  1. HR1922, the 'Ensuring Access to Essential Drugs Act,' was introduced on March 6, 2025 by Rep. Garbarino (R-NY) with two cosponsors. It has been referred to both the Energy and Commerce and Ways and Means Committees. No further actions have occurred. 2) The bill does not authorize or appropriate any funding. It modifies the Medicare Part D Manufacturer Discount Program to exempt specific orally administered brand-name drugs that have been reclassified as noninnovator multiple source drugs under Medicaid. This is a regulatory exemption, not a spending bill. 3) No specific publicly traded companies are directly named in the bill text. The exemption would apply to a narrow, undefined set of drugs requiring a CMS exception. Without knowing which drugs or manufacturers hold such exceptions, no ticker-level analysis is possible. 4) The bill has zero legislative velocity — two committee referrals on the same day and no actions since. No companion bill in the Senate. 5) Next steps would require committee hearings, markup, floor votes in both chambers, and presidential action. Given the early stage and narrow scope, meaningful market impact is years away if it advances at all.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderAug 10, 2026

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.

Exec OrderAug 6, 2026

Continuing to Protect the Meaning and Value of American Citizenship

This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.

Exec OrderAug 6, 2026

Ending Birth Tourism

This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →